Please wait while the formulary information is being retrieved.
ORPHENADRINE CITRATE (ORPHENADRINE CITRATE)
- Muscle spasm
30 mg/mL injection solution
- Inject 2 milliliters (60 mg) by intramuscular route every 12 hours asneeded
30 mg/mL injection solution
- Inject 2 milliliters (60 mg) by intramuscular route every 12 hours asneeded
Muscle spasm
- Inject 2 milliliters (60 mg) by intravenous route every 12 hours as needed
- Inject 2 milliliters (60 mg) by intramuscular route every 12 hours asneeded
- None
Contraindicated
- None
Severe
Moderate
- None
- Achalasia of esophagus
- Benign prostatic hyperplasia
- Bladder outflow obstruction
- Duodenal obstruction
- Glaucoma
- Myasthenia gravis
- Pyloroduodenal obstruction
- Stenosing peptic ulcer
Contraindicated
- None
Severe
Moderate
- Acute decompensated heart failure
- Cardiac arrhythmia
- Chronic myocardial ischemia
- Disease of liver
- Tachyarrhythmia
ORPHENADRINE CITRATE (ORPHENADRINE CITRATE)
- Muscle spasm
- None
- None
More Frequent
Severe
Less Severe
- Ocular hypertension
- Oliguria
- Palpitations
- Syncope
- Tachycardia
- Abdominal pain with cramps
- Acute confusion
- Blurred vision
- Constipation
- Diplopia
- Dizziness
- Drowsy
- Dysuria
- Headache disorder
- Insomnia
- Nausea
- Nervousness
- Tremor
- Visual changes
- Vomiting
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Aplastic anemia
- Hallucinations
- Pancytopenia
Less Severe
- Muscle weakness
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Orphenadrine
Safety and efficacy not established in children age less than 12 years.
- 1 Day – 12 Years
- Safety and efficacy not established in children age less than 12 years.
Orphenadrine Hcl
- Severity Level:
C
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Orphenadrine
Insufficient data available.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Orphenadrine
Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- None
| Muscle spasm | |
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
| 0-9 | A-Z |
|---|---|
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
Formulary Reference Tool